Medivation Inc. Newsletter
-
Pfizer & Astellas Pharma announces positive results from phase 3 EMBARK study of Xtandi plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with BCR
11 Jul 2025 04:33 GMT
… globally.
In October 2009, Medivation, Inc., which is now … States.
Astellas Pharma Inc. is a pharmaceutical company conducting … continuous creation of new drugs to address diseases … including small molecules, antibody-drug conjugates (ADCs), and bispecific …
-
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
09 Jul 2025 17:58 GMT
… Myers Corp billion largest Squibb pharmaceutical mergers in history 2017 Johnson … cancer 2016 Pfizer Medivation $14 Pfizer billion acquires blockbuster prostate cancer drug Xtandi 2015 …
-
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
12 Jun 2025 13:56 GMT
… sorts, to Medivation, which developed the prostate cancer drug Xtandi and … is run by David Hung, Medivation’s former CEO, and … company scrapped its initial drug program in 2022 and changed … .
There are multiple similar drugs available for ROS1-positive lung …
-
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
11 Jun 2025 17:35 GMT
… Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and … phosphokinase (5%).
DRUG INTERACTIONS
Strong and Moderate CYP3A … NUV-1511, an innovative drug-drug conjugate (DDC) designed … D., who previously founded Medivation, Inc., which brought …
-
Medicare Drug Pricing Reform Brings Financial Relief to Patients
13 Jan 2025 20:00 GMT
… in 2024 when Medicare limited drug costs to $3500, a … . A $2000 cap on OOP drug spending would have yielded savings … $5694.57 for enzalutamide (Xtandi; Medivation, Inc) to $9872.12 for … the financial strain of prescription drugs, this policy offers a vital …
-
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
23 Dec 2024 13:11 GMT
… Taletrectinib previously received Orphan Drug Designation and is the … has been granted Orphan Drug Designation by the U. … M.D., who previously founded Medivation, Inc., which brought to … challenges associated with conducting drug discovery and initiating or …
-
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
14 Sep 2024 08:50 GMT
… has been granted Orphan Drug Designation by the U.S … Review Designations to New Drug Applications for taletrectinib for … M.D., who previously founded Medivation, Inc., which brought to … challenges associated with conducting drug discovery and initiating or …
-
Fallopian Tube Cancer Pipeline Assessment, 2024 Updates | In-Depth Insights Into The Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Companies | Immunogen, Janssen R&D
28 May 2024 21:02 GMT
… therapeutic assessment of the pipeline drugs by the Route of Administration … , OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/;Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab …
-
Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com
13 Mar 2024 13:11 GMT
…
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals …
MediGene
Medigus
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
MEI Pharma
Melmed
Memory Dx …
-
Eli Lilly aims to introduce Alzheimer’s drug Donanemab in India in near future: CEO Dave Ricks
29 Feb 2024 09:35 GMT
American pharmaceutical giant Eli Lilly plans to introduce its Alzheimer’s drug, … slow its progression. These drugs primarily fall into two categories … Aduhelm, the first FDA-approved drug targeting beta-amyloid; Eisai, … through their acquisition of Medivation.